Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
BMO Capital to hold a virtual conference » 08:41
06/23/20
06/23
08:41
06/23/20
08:41
ANTM

Anthem

$265.10 /

-1.41 (-0.53%)

, IMUX

Immunic

$14.17 /

+0.36 (+2.61%)

, SRRK

Scholar Rock

$19.09 /

+0.27 (+1.43%)

, EHC

Encompass Health

$63.73 /

-0.48 (-0.75%)

, FLXN

Flexion

$12.71 /

-0.02 (-0.16%)

, REGN

Regeneron

$627.91 /

-15.055 (-2.34%)

, SLGL

Sol-Gel Technologies

$8.44 /

+0.2 (+2.43%)

, MORF

Morphic Holding

$29.62 /

+2.45 (+9.02%)

, MNK

Mallinckrodt

$2.91 /

+0.355 (+13.89%)

, ETTX

Entasis Therapeutics

$2.99 /

-0.035 (-1.16%)

, AGTC

Applied Genetic

$6.39 /

+0.255 (+4.16%)

, HZNP

Horizon Therapeutics

$52.52 /

+2.545 (+5.09%)

, BBIO

BridgeBio

$33.07 /

+1.06 (+3.31%)

, AQST

Aquestive Therapeutics

$5.42 /

+0.01 (+0.18%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

, CNC

Centene

$63.09 /

-1.08 (-1.68%)

, LNTH

Lantheus

$13.99 /

-0.58 (-3.98%)

, SDGR

Schrodinger

$75.65 /

+0.49 (+0.65%)

, SCPH

scPharmaceuticals

$7.55 /

+0.35 (+4.86%)

, PHAT

Phathom Pharmaceuticals

$45.36 /

-0.635 (-1.38%)

, HUM

Humana

$379.31 /

-1.3 (-0.34%)

, HARP

Harpoon Therapeutics

$18.18 /

-0.02 (-0.11%)

Prescriptions for Success…

Prescriptions for Success Healthcare Virtual Conference will be held on June 23 at 9 am. Webcast Link

ShowHide Related Items >><<
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

06/05/20 Goldman Sachs
Anthem initiated with a Neutral at Goldman Sachs
06/01/20 Piper Sandler
Kentucky contract positive for Molina, negative for Anthem, says Piper Sandler
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
IMUX Immunic
$14.17 /

+0.36 (+2.61%)

06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

05/29/20 Mizuho
Encompass Health price target lowered to $87 from $90 at Mizuho
04/20/20 BMO Capital
Encompass Health price target raised to $83 from $66 at BMO Capital
03/06/20 Deutsche Bank
Encompass Health price target raised to $83 from $73 at Deutsche Bank
03/05/20 BMO Capital
Encompass Health price target raised to $95 from $88 at BMO Capital
FLXN Flexion
$12.71 /

-0.02 (-0.16%)

05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Flexion initiated with a Buy at Guggenheim
05/08/20 Needham
Flexion price target lowered to $20 from $30 at Needham
04/02/20 Benchmark
Flexion price target lowered to $17 from $25 at Benchmark
REGN Regeneron
$627.91 /

-15.055 (-2.34%)

06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

05/08/20 BMO Capital
Entasis Therapeutics price target lowered to $5 from $15 at BMO Capital
04/14/20 H.C. Wainwright
Entasis Therapeutics price target lowered to $5 from $18 at H.C. Wainwright
08/19/19 H.C. Wainwright
Entasis Therapeutics initiated with a Buy at H.C. Wainwright
AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

06/23/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
06/22/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

06/10/20 Mizuho
Mizuho doctor survey shows preference for SEL-212 over Krystexxa
05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
CNC Centene
$63.09 /

-1.08 (-1.68%)

04/29/20 Oppenheimer
Centene price target raised to $90 from $83 at Oppenheimer
04/29/20 Piper Sandler
Centene selloff yesterday a buying opportunity, says Piper Sandler
04/09/20 Jefferies
Anthem downgraded to Hold on Commercial Risk at Jefferies
LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

06/16/20 CJS Securities
Lantheus upgraded to Outperform from Market Perform at CJS Securities
10/02/19 Credit Suisse
Lantheus deal for Progenics has 'some strategic merit,' says Credit Suisse
08/16/19
Lantheus upgraded to Outperform from Market Perform at CJS Securities
SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

06/02/20 BMO Capital
Schrodinger price target raised to $85 from $67 at BMO Capital
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Jefferies
Schrodinger initiated with a Hold at Jefferies
03/02/20 Morgan Stanley
Schrodinger initiated with an Equal Weight at Morgan Stanley
SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
10/15/19 H.C. Wainwright
scPharmaceuticals initiated with a Buy at H.C. Wainwright
PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
HUM Humana
$379.31 /

-1.3 (-0.34%)

06/18/20 Deutsche Bank
Humana price target lowered to $397 from $421 at Deutsche Bank
06/17/20 Cantor Fitzgerald
Humana price target raised to $410 from $405 at Cantor Fitzgerald
06/16/20 Cowen
Humana downgraded to Market Perform on valuation at Cowen
06/16/20 Cowen
Humana downgraded to Market Perform from Outperform at Cowen
HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

06/01/20 Wedbush
Harpoon Therapeutics price target raised to $36 from $26 at Wedbush
06/01/20 Piper Sandler
Harpoon initial data for HPN424 'highly encouraging,' says Piper Sandler
05/29/20 Roth Capital
Harpoon Therapeutics price target raised to $31 from $25 at Roth Capital
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

Recommendations
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi » 07:06
06/17/20
06/17
07:06
06/17/20
07:06
MNK

Mallinckrodt

$2.69 /

+0.115 (+4.47%)

, ENDP

Endo

$3.71 /

+0.16 (+4.51%)

Opioid risk is coming…

Opioid risk is coming back after the office of the New York attorney general affirmed that pre-trial proceedings are on schedule to be completed by August 4, Citi analyst Navann Ty tells investors in a research note. The New York opioid trial was set to begin on March 20, but was delayed because of COVID-19, the analyst points out. Ty remains Buy on Endo (ENDP), believing the "low opioid settlements to date and their rationale may help with future negotiations." The analyst expects penalties to not exceed low-three digit million. Ty recommends selling shares of Mallinckrodt (MNK). Absent a successful appeal, the Centers for Medicare and Medicaid Services ruling may lead to rescinding of the agreed-in-principle opioid settlement, which may threaten Mallinckrodt's continuation as a going concern, says the analyst.

ShowHide Related Items >><<
MNK Mallinckrodt
$2.69 /

+0.115 (+4.47%)

ENDP Endo
$3.71 /

+0.16 (+4.51%)

MNK Mallinckrodt
$2.69 /

+0.115 (+4.47%)

05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
ENDP Endo
$3.71 /

+0.16 (+4.51%)

04/24/20 Citi
Endo initiated with a Buy at Citi
01/03/20 Piper Sandler
Endo upgraded to Overweight from Neutral at Piper Jaffray
09/11/19 Guggenheim
Endo assumed with a Neutral at Guggenheim
MNK Mallinckrodt
$2.69 /

+0.115 (+4.47%)

ENDP Endo
$3.71 /

+0.16 (+4.51%)

MNK Mallinckrodt
$2.69 /

+0.115 (+4.47%)

ENDP Endo
$3.71 /

+0.16 (+4.51%)

MNK Mallinckrodt
$2.69 /

+0.115 (+4.47%)

ENDP Endo
$3.71 /

+0.16 (+4.51%)

MNK Mallinckrodt
$2.69 /

+0.115 (+4.47%)

ENDP Endo
$3.71 /

+0.16 (+4.51%)

Hot Stocks
Mallinckrodt to proceed with appeal despite court decision denying injunction » 10:54
06/15/20
06/15
10:54
06/15/20
10:54
MNK

Mallinckrodt

$2.39 /

-0.11 (-4.40%)

Mallinckrodt announced…

Mallinckrodt announced its disappointment with the U.S. Court of Appeals for the District of Columbia decision to deny its request for a temporary injunction preventing the U.S. Centers for Medicare and Medicaid Services, or CMS, from enforcing a change in Medicaid drug rebate calculation for Acthar Gel. Mallinckrodt said in a release, "Mallinckrodt had asked for the temporary injunction as it appeals a lower court ruling that allowed CMS to reset the base date average manufacturer price, or AMP. The Appeals Court also ordered an expedited briefing and oral argument schedule that will likely lead to fall oral arguments, and potentially a ruling by end of year. As a result of today's appeals court ruling, Mallinckrodt will change the base date AMP for Acthar Gel, as directed by CMS. The effect of the change is an immediate recognition of retroactive non-recurring charges (estimated at approximately $650 million through mid-June) and the prospective loss of Acthar Medicaid net sales, which has historically contributed to Acthar Gel net sales of $90 to $100 million annually. The company will continue to appeal the March 16 ruling by the U.S. District Court for the District of Columbia that upheld CMS' position. Barring other arrangements, the cash payments for retroactive Medicaid rebate charges will be processed over time, in accordance with the normal rebate payment schedule, and the company expects the cash outlays will most likely commence in the fourth quarter of 2020. Despite the ruling, Mallinckrodt remains committed to ensuring that Medicaid patients have access to Acthar Gel." Mallinckrodt Chief Legal Officer Mark Casey said, "We are disappointed in the appeals court decision not to issue a temporary injunction to prevent CMS from enforcing this change in Medicaid rebate calculations while our case is still under appeal. We will continue our appeal, which could be decided as early as end of year, and strongly believe that the District Court misinterpreted the statute that governs the Medicaid drug rebate program and failed to hold CMS accountable to the Administrative Procedure Act. CMS twice confirmed in writing its approval of the Acthar Gel Medicaid rebate calculation in use today, before it later reversed its position without giving fair notice or any clear legal basis for doing so."

ShowHide Related Items >><<
MNK Mallinckrodt
$2.39 /

-0.11 (-4.40%)

MNK Mallinckrodt
$2.39 /

-0.11 (-4.40%)

05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
MNK Mallinckrodt
$2.39 /

-0.11 (-4.40%)

MNK Mallinckrodt
$2.39 /

-0.11 (-4.40%)

MNK Mallinckrodt
$2.39 /

-0.11 (-4.40%)

MNK Mallinckrodt
$2.39 /

-0.11 (-4.40%)

Hot Stocks
Mallinckrodt announces terlipressin medical chart study published » 06:56
06/11/20
06/11
06:56
06/11/20
06:56
MNK

Mallinckrodt

$2.80 /

-0.24 (-7.89%)

Mallinckrodt announced…

Mallinckrodt announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors in hospitalized patients with hepatorenal syndrome type 1, or HRS-1, an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis. The study, funded by Mallinckrodt, found that terlipressin was associated with an improvement in kidney function among HRS-1 patients as measured by a reduction in serum creatinine, or SCr. The results of the study were published in the peer-reviewed journal Alimentary Pharmacology and Therapeutics. Mallinckrodt is investigating terlipressin for the treatment of HRS-1 in the U.S. Its safety and effectiveness have not yet been established by the FDA. Medical records of 250 adult patients with HRS-1 from 26 centers in the U.K. were reviewed, 225 of whom were treated with vasopressor therapy. The majority of patients were treated with terlipressin with a median duration of therapy of six days, in line with European Association for the Study of the Liver, or EASL, guidelines recommending terlipressin for first-line use in patients with HRS-1. A complete response was observed in 50% of patients treated with terlipressin and 23% of those treated with other vasopressors. Overall response, as measured by a complete response or partial response, was demonstrated in 73% of patients treated with terlipressin and 59% treated with other vasopressors. In addition, lower SCr at the time of treatment initiation was associated with higher complete response rates.

ShowHide Related Items >><<
MNK Mallinckrodt
$2.80 /

-0.24 (-7.89%)

MNK Mallinckrodt
$2.80 /

-0.24 (-7.89%)

05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
MNK Mallinckrodt
$2.80 /

-0.24 (-7.89%)

MNK Mallinckrodt
$2.80 /

-0.24 (-7.89%)

MNK Mallinckrodt
$2.80 /

-0.24 (-7.89%)

MNK Mallinckrodt
$2.80 /

-0.24 (-7.89%)

Hot Stocks
Mallinckrodt completes rolling submission of BLA of StrataGraft to FDA » 15:39
06/09/20
06/09
15:39
06/09/20
15:39
MNK

Mallinckrodt

$2.99 /

+0.055 (+1.88%)

Mallinckrodt announced…

Mallinckrodt announced earlier that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application, or BLA, to the FDA for StrataGraft, a regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns. The company previously announced initiation of the rolling submission in April. StrataGraft skin tissue is an investigational product, and its safety and effectiveness have not yet been established by the FDA.

ShowHide Related Items >><<
MNK Mallinckrodt
$2.99 /

+0.055 (+1.88%)

MNK Mallinckrodt
$2.99 /

+0.055 (+1.88%)

05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
MNK Mallinckrodt
$2.99 /

+0.055 (+1.88%)

MNK Mallinckrodt
$2.99 /

+0.055 (+1.88%)

MNK Mallinckrodt
$2.99 /

+0.055 (+1.88%)

MNK Mallinckrodt
$2.99 /

+0.055 (+1.88%)

Over a month ago
Hot Stocks
Mallinckrodt to appeal District Court ruling » 06:57
06/01/20
06/01
06:57
06/01/20
06:57
MNK

Mallinckrodt

$2.83 /

-0.07 (-2.42%)

Mallinckrodt announced…

Mallinckrodt announced that it will appeal a ruling by the U.S. District Court for the District of Columbia in a lawsuit filed by its subsidiary, Mallinckrodt ARD LLC, against the U.S. Department of Health and Human Services, or HHS, and the Centers for Medicare and Medicaid Services, or CMS, regarding the Medicaid drug rebate calculation for Acthar Gel. "The District Court denied the Company's request to reconsider its previous decision that declined to declare unlawful an action by CMS to effectuate a change in the base date average manufacturer price used to calculate those rebates. The Court also denied the company's request that it temporarily block CMS' action pending an appeal. The Company will immediately appeal to the U.S. Court of Appeals for the D.C. Circuit, where it will seek to overturn the lower court decision and temporarily block CMS action during the appellate process," the company said in a release. "We are disappointed by the Court's unwillingness to reconsider its previous decision. We believe the Court has misinterpreted the statute that governs the Medicaid drug rebate program and failed to hold the government accountable to a bedrock principle of administrative law that the government must give fair notice and a clear, legal basis for a change in policy, particularly when that policy has been relied upon by a regulated entity such as Mallinckrodt," said Mark Casey, Executive Vice President and Chief Legal Officer of Mallinckrodt. "We plan to immediately appeal to the U.S. Court of Appeals for the D.C. Circuit. Mallinckrodt remains committed to ensuring Medicaid patients have access to Acthar Gel therapy for the long term." The company added, "In asking the Court to temporarily block CMS' action, the Company described the risk that allowing CMS to move forward could inhibit the Company's ability to fund research and development activities, including COVID-19 related activities, and effectuate its opioid settlement, among other issues. As previously announced, in the absence of court intervention, the company would pay roughly $640 million in retroactive non-recurring charges from January 1, 2013 to March 27, 2020, and the annualized prospective change to the Medicaid rebate calculation would reduce Acthar Gel net sales by roughly $90 million to $100 million. Under a previous agreement with the government, CMS has agreed to not enforce a change in the Medicaid drug rebate calculation for Acthar Gel until at least June 14."

ShowHide Related Items >><<
MNK Mallinckrodt
$2.83 /

-0.07 (-2.42%)

MNK Mallinckrodt
$2.83 /

-0.07 (-2.42%)

05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
MNK Mallinckrodt
$2.83 /

-0.07 (-2.42%)

MNK Mallinckrodt
$2.83 /

-0.07 (-2.42%)

MNK Mallinckrodt
$2.83 /

-0.07 (-2.42%)

MNK Mallinckrodt
$2.83 /

-0.07 (-2.42%)

Downgrade
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan » 06:11
05/19/20
05/19
06:11
05/19/20
06:11
MNK

Mallinckrodt

$3.34 /

+0.22 (+7.05%)

JPMorgan analyst…

JPMorgan analyst Christopher Schott downgraded Mallinckrodt to Underweight from Neutral without a price target. With the fundamental story "looking increasingly challenged" amid Acthar, Inomax and Ofirmev erosion, and multiple legal challenges facing the business, Mallinckrodt does not have a clear path to a turnaround, Schott tells investors in a research note.

ShowHide Related Items >><<
MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

Downgrade
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan » 05:32
05/19/20
05/19
05:32
05/19/20
05:32
MNK

Mallinckrodt

$3.34 /

+0.22 (+7.05%)

JPMorgan analyst…

JPMorgan analyst Christopher Schott downgraded Mallinckrodt to Underweight from Neutral.

ShowHide Related Items >><<
MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

MNK Mallinckrodt
$3.34 /

+0.22 (+7.05%)

On The Fly
Fly Intel: Pre-market Movers » 09:08
05/05/20
05/05
09:08
05/05/20
09:08
ALXN

Alexion

$103.89 /

-0.07 (-0.07%)

, PTLA

Portola Pharmaceuticals

$7.76 /

+0.73 (+10.38%)

, TGTX

TG Therapeutics

$12.47 /

+1.22 (+10.84%)

, DD

DuPont

$44.67 /

-0.36 (-0.80%)

, SYY

Sysco

$53.84 /

+1.08 (+2.05%)

, MPC

Marathon Petroleum

$31.56 /

+2.31 (+7.90%)

, HSIC

Henry Schein

$52.60 /

+0.44 (+0.84%)

, IPGP

IPG Photonics

$118.77 /

-0.48 (-0.40%)

, USFD

US Foods

$19.94 /

+0.48 (+2.47%)

, SEE

Sealed Air

$27.23 /

-1 (-3.54%)

, ALK

Alaska Air

$28.69 /

-1.31 (-4.37%)

, W

Wayfair

$134.14 /

+11.49 (+9.37%)

, WRK

WestRock

$30.29 /

-0.57 (-1.85%)

, MNK

Mallinckrodt

$3.30 /

-0.055 (-1.64%)

, LITE

Lumentum

$78.44 /

+0.94 (+1.21%)

, HTZ

Hertz

$3.59 /

+0.085 (+2.43%)

, LB

L Brands

$12.05 /

+0.06 (+0.50%)

, KPTI

Karyopharm

$20.68 /

+1.35 (+6.98%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ALXN Alexion
$103.89 /

-0.07 (-0.07%)

04/27/20 Cantor Fitzgerald
Alexion initiated with a Neutral at Cantor Fitzgerald
04/21/20 Baird
Alexion thesis unchanged following Ultomiris advance, says Baird
04/20/20 Morgan Stanley
Court claim construction largely favors Chugai over Alexion, says Morgan Stanley
03/17/20 Oppenheimer
Alexion downgraded to Perform at Oppenheimer
PTLA Portola Pharmaceuticals
$7.76 /

+0.73 (+10.38%)

04/23/20
Fly Intel: Top five analyst initiations
04/23/20 RBC Capital
Portola Pharmaceuticals initiated with an Outperform at RBC Capital
01/10/20 Cowen
Portola Pharmaceuticals price target lowered to $35 from $45 at Cowen
01/10/20 Oppenheimer
Oppenheimer downgrades Portola on Andexxa headwinds, cuts target to $17
TGTX TG Therapeutics
$12.47 /

+1.22 (+10.84%)

01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
01/17/20 H.C. Wainwright
TG Therapeutics price target raised to $24 from $20 at H.C. Wainwright
01/09/20 B. Riley FBR
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
12/09/19 B. Riley FBR
TG Therapeutics price target raised to $17 from $12 at B. Riley FBR
DD DuPont
$44.67 /

-0.36 (-0.80%)

04/29/20
Fly Intel: Top five analyst initiations
04/29/20 Wells Fargo
DuPont initiated with an Overweight at Wells Fargo
04/20/20
Fly Intel: Top five analyst upgrades
04/20/20 BMO Capital
DuPont price target lowered to $55 from $75 at BMO Capital
SYY Sysco
$53.84 /

+1.08 (+2.05%)

04/23/20
Fly Intel: Top five analyst downgrades
04/23/20 BMO Capital
Sysco downgraded to Market Perform from Outperform at BMO Capital
04/06/20 JPMorgan
Sysco price target lowered to $47 from $78 at JPMorgan
03/26/20
Fly Intel: Top five analyst upgrades
MPC Marathon Petroleum
$31.56 /

+2.31 (+7.90%)

04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
03/24/20 Raymond James
Marathon Petroleum downgraded to Market Perform from Strong Buy at Raymond James
03/19/20 BofA
MPLX upgraded to Buy from Neutral at BofA
HSIC Henry Schein
$52.60 /

+0.44 (+0.84%)

04/07/20 Goldman Sachs
Henry Schein upgraded to Buy from Neutral at Goldman Sachs
04/02/20 Wolfe Research
Henry Schein upgraded to Outperform from Peer Perform at Wolfe Research
02/07/20 Cleveland Research
Large dental manufacturer seen exploring direct move, says Cleveland Research
01/09/20 BofA
Henry Schein downgraded to Underperform from Neutral at BofA
IPGP IPG Photonics
$118.77 /

-0.48 (-0.40%)

02/14/20 DA Davidson
IPG Photonics price target raised to $170 from $150 at DA Davidson
02/13/20 Piper Sandler
IPG Photonics price target cut to $150 from $155 at Piper Sandler
01/29/20 Stifel
IPG Photonics downgraded to Hold from Buy at Stifel
12/20/19 Piper Sandler
IPG Photonics initiated with a Neutral at Piper Jaffray
USFD US Foods
$19.94 /

+0.48 (+2.47%)

04/27/20 Credit Suisse
US Foods price target lowered to $27 from $47 at Credit Suisse
04/23/20 BMO Capital
US Foods downgraded to Market Perform from Outperform at BMO Capital
04/06/20 JPMorgan
US Foods price target lowered to $24 from $45 at JPMorgan
03/17/20 Wells Fargo
US Foods covenant update not as bad as feared, says Wells Fargo
SEE Sealed Air
$27.23 /

-1 (-3.54%)

04/27/20
Fly Intel: Top five analyst downgrades
04/26/20 BMO Capital
Sealed Air downgraded to Market Perform from Outperform at BMO Capital
02/12/20 Baird
Sealed Air designated as Fresh Pick at Baird
12/19/19
Fly Intel: Top five analyst upgrades
ALK Alaska Air
$28.69 /

-1.31 (-4.37%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
Alaska Air price target lowered to $35 from $44 at Barclays
04/21/20 Deutsche Bank
Alaska Air price target lowered to $45 from $52 at Deutsche Bank
04/12/20
Airlines want Treasury to scrap proposal to make grant repayable, Reuters says
W Wayfair
$134.14 /

+11.49 (+9.37%)

05/04/20 Credit Suisse
Wayfair price target raised to $135 from $110 at Credit Suisse
05/04/20 Piper Sandler
Wayfair price target raised to $140 from $100 at Piper Sandler
05/01/20 Oppenheimer
Wayfair price target raised to $160 from $120 at Oppenheimer
04/29/20 Wedbush
Wayfair price target raised to $145 from $75 at Wedbush
WRK WestRock
$30.29 /

-0.57 (-1.85%)

04/09/20 KeyBanc
WestRock price target lowered to $27 from $34 at KeyBanc
04/07/20 Goldman Sachs
Goldman cuts paper and packaging estimates, prefers Ball and Graphic Packaging
02/28/20 Stephens
Paper companies should take 'closer look' at their dividends, says Stephens
02/13/20 BofA
Paused project a positive for containerboard market, says BofA
MNK Mallinckrodt
$3.30 /

-0.055 (-1.64%)

04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
LITE Lumentum
$78.44 /

+0.94 (+1.21%)

04/24/20 Rosenblatt
NeoPhotonics downgraded to Neutral at Rosenblatt with stock near three-year high
04/17/20 Goldman Sachs
Lumentum downgraded to Sell from Neutral at Goldman Sachs
03/27/20 Craig-Hallum
Lumentum price target lowered to $95 from $105 at Craig-Hallum
02/05/20 DA Davidson
Lumentum price target raised to $100 from $75 at DA Davidson
HTZ Hertz
$3.59 /

+0.085 (+2.43%)

04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
04/23/20 JPMorgan
JPMorgan sees rental cars as 'worst positioned,' cuts Hertz to Underweight
LB L Brands
$12.05 /

+0.06 (+0.50%)

05/05/20 Deutsche Bank
L Brands price target lowered to $16 from $24 at Deutsche Bank
05/05/20 BMO Capital
BMO upgrades L Brands after Sycamore deal ends, sees 50%-70% upside
05/05/20 BMO Capital
L Brands upgraded to Outperform from Market Perform at BMO Capital
04/24/20 Deutsche Bank
Deutsche reiterates Buy on L Brands, sees Sycamore deal closing
KPTI Karyopharm
$20.68 /

+1.35 (+6.98%)

04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
03/03/20 Canaccord
Karyopharm price target raised to $35 from $22 at Canaccord
Hot Stocks
Mallinckrodt down 7.6% after reporting Q1 results  08:09
05/05/20
05/05
08:09
05/05/20
08:09
MNK

Mallinckrodt

$3.30 /

-0.055 (-1.64%)

 
ShowHide Related Items >><<
MNK Mallinckrodt
$3.30 /

-0.055 (-1.64%)

04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Mallinckrodt initiated with a Sell at Citi
02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.